Free tool
FAERS Monitor: Veltassa
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 205739 or its brand name (Veltassa, Patiromer Sorbitex Calcium). Reports on generic versions are filed under their own applications.
Reports
13,806
Serious
6,761
49% of reports
Hospitalization
3,806
Death reported
2,126
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- constipation2,146
- death1,832
- diarrhoea1,296
- hospitalisation980
- off label use941
- blood potassium increased802
- nausea713
- drug dose omission672
- malaise584
- abdominal discomfort541
- inappropriate schedule of drug administration461
- vomiting450
- abdominal pain upper427
- no adverse event377
- dyspnoea374
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2016 | 3,462 |
| 2017 | 4,594 |
| 2018 | 1,774 |
| 2019 | 1,327 |
| 2020 | 896 |
| 2021 | 569 |
| 2022 | 313 |
| 2023 | 192 |
| 2024 | 191 |
| 2025 | 318 |
| 2026 | 170 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,040,353 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| blood potassium increasedSignal | 802 | 79.1 | 73.9 | 58,793 |
| constipationSignal | 2,146 | 15.1 | 14.5 | 28,320 |
| inappropriate schedule of drug administrationSignal | 461 | 9.9 | 9.1 | 3,682 |
| hospitalisationSignal | 980 | 9.8 | 9.2 | 7,716 |
| drug dose omissionSignal | 672 | 6.2 | 5.8 | 2,946 |
| abdominal discomfortSignal | 541 | 4.9 | 4.5 | 1,697 |
| deathSignal | 1,832 | 3.2 | 3.1 | 2,957 |
| no adverse eventSignal | 377 | 3.2 | 2.9 | 563 |
| abdominal pain upperSignal | 427 | 3.2 | 2.9 | 635 |
| diarrhoeaSignal | 1,296 | 3.1 | 2.9 | 1,852 |
| malaiseSignal | 584 | 2.0 | 1.9 | 310 |
| off label use | 941 | 1.6 | 1.5 | 243 |
| vomiting | 450 | 1.5 | 1.3 | 66 |
| nausea | 713 | 1.4 | 1.3 | 75 |
| dyspnoea | 374 | 1.0 | 0.9 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.